Aetna covers Wegovy on most commercial plans as of July 2025, when CVS Caremark named it the preferred GLP-1 medication on Aetna’s formulary. Coverage requires prior authorization and depends on which specific plan a member holds. Self-funded employer plans and Aetna Medicare Advantage plans follow different coverage rules.
Most Aetna Standard and ACA marketplace plans cover Wegovy for members with a BMI of 30 or higher, or BMI of 27 with a weight-related condition. Prior authorization requires 6 months of documented lifestyle efforts. A cardiovascular pathway opened in 2024 for adults with established heart disease. Medicare Advantage covers Wegovy for cardiovascular use only.
If Aetna denies a claim, 65 percent of well-documented appeals succeed. Wegovy’s cash price reaches $1,349 to $1,800 per month without coverage. This guide covers plan types, prior authorization steps, appeal strategies, and cost-saving alternatives for Aetna members in 2026.
Does Aetna Cover Wegovy?
Yes. Aetna covers Wegovy on most commercial plans as the preferred GLP-1 medication since CVS Caremark updated its formulary in July 2025. That’s significant news for Aetna members seeking this medication. Prior authorization is still required, but coverage is now more widely available than before that formulary shift.
Here’s the thing: coverage depends entirely on which specific Aetna plan a member holds. Employer-sponsored commercial plans and ACA marketplace plans are the most likely to include Wegovy. Self-funded employer plans run on separate formularies and can exclude weight loss medications altogether. Two people with identical Aetna cards from different employers can have completely different access to Wegovy.
The July 2025 formulary change transformed the landscape for most Aetna commercial members. Before that date, Wegovy coverage was inconsistent and often plan-specific. Members should call Aetna member services directly or search the drug formulary on the Aetna website to confirm their specific plan’s status.
Is Wegovy the Preferred GLP-1 on Aetna’s Formulary?
Yes. Wegovy became the preferred GLP-1 receptor agonist on CVS Caremark formularies in July 2025 after Novo Nordisk negotiated a preferred placement deal with the pharmacy benefit manager. Why does that matter? CVS Health owns both CVS Caremark and Aetna, so the formulary change reached a large portion of Aetna members simultaneously.
Preferred status means lower cost-sharing for members compared to non-preferred GLP-1 alternatives. Zepbound (tirzepatide) remains on Aetna’s formulary but sits at a higher tier, which translates to higher copays for most plans. Preferred placement does not eliminate prior authorization requirements, but it does reduce the out-of-pocket burden for members who qualify.
Which Aetna Plans Cover Wegovy?
Aetna’s commercial health insurance plans are the most likely to include Wegovy coverage, with Standard plans, Advanced Control plans, and most ACA marketplace plans listing Wegovy on their formulary as of mid-2025. The picture is more restricted for self-funded employer plans and government-sponsored plans.
Self-funded employer plans follow their own formularies, which Aetna administers but does not design. These plans frequently exclude weight loss medications as a cost-control measure. Aetna Medicare Advantage plans have limited coverage due to federal Medicare statutes. Some state Medicaid plans, including Oklahoma’s Aetna Better Health, cover Wegovy, while most others do not.
Aetna Plan Types and Wegovy Coverage Status:
| Plan Type | Wegovy Coverage | PA Required |
|---|---|---|
| Standard Commercial | Yes (preferred since July 2025) | Yes |
| Advanced Control | Yes | Yes |
| ACA Marketplace | Usually yes | Yes |
| Self-Funded Employer | Varies by employer plan | Varies |
| Aetna Medicare Advantage | Limited (cardiovascular use only) | Yes |
| Aetna Medicaid | State-dependent | Varies |
What Is Wegovy?
Wegovy is a brand-name injectable medication containing semaglutide 2.4 mg, developed by Novo Nordisk and approved by the FDA for chronic weight management in adults and adolescents aged 12 and older with obesity or overweight. It belongs to the GLP-1 receptor agonist drug class and works by mimicking a gut hormone that reduces appetite and slows gastric emptying.
Semaglutide was first approved at a lower dose as Ozempic for type 2 diabetes management. Wegovy uses the higher 2.4 mg dose specifically for weight management. The two medications are not interchangeable under Aetna coverage policies. Ozempic prescribed off-label for weight loss is typically not covered.
Wegovy requires a weekly subcutaneous injection starting at 0.25 mg, with gradual dose increases over 16 to 20 weeks to reach the 2.4 mg maintenance dose. Aetna requires patients to combine Wegovy with a reduced-calorie diet and increased physical activity as a condition of coverage under any approved indication.
What Are Wegovy’s FDA-Approved Uses?
The FDA has approved Wegovy for three distinct indications: chronic weight management, cardiovascular risk reduction in adults with established cardiovascular disease, and treatment of metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis. Each indication has separate prior authorization criteria at Aetna.
The weight management indication covers adults with a BMI of 30 kg per square meter (11.7 lb per square foot) or higher, or adults with a BMI of 27 kg per square meter (10.5 lb per square foot) who have at least one weight-related comorbid condition. Adolescents aged 12 and older with a BMI at or above the 95th percentile for their age and sex also qualify.
The cardiovascular indication, approved in March 2024, targets adults with prior heart attack, stroke, or established atherosclerotic cardiovascular disease who are also obese or overweight. The MASH indication covers adults with confirmed F2 to F3 liver fibrosis by noninvasive testing. These additional pathways open coverage options for patients who may not qualify under the standard weight management BMI criteria alone.
Does Aetna Require Prior Authorization for Wegovy?
Yes. Aetna requires prior authorization for Wegovy under all plan types that include the medication on their formulary, and the PA demonstrates medical necessity through documentation submitted by the healthcare provider. This is standard practice for high-cost specialty medications in the GLP-1 class.
In plain English: the patient does not submit the prior authorization. The prescribing provider does. The provider sends clinical documentation to Aetna for review, and Aetna returns a coverage decision. Timelines vary by plan, but most decisions come back within a few business days to one week.
The PA approval for initial therapy lasts 7 months. Continuation of therapy then requires a new approval lasting 12 months. Missing a renewal deadline can interrupt coverage and require restarting the authorization process. Patients should confirm renewal timelines with their provider well before the initial period closes.
What BMI Is Required for Wegovy Coverage?
Adults need a BMI of 30 kg per square meter (11.7 lb per square foot) or higher for obesity-based coverage, or a BMI of at least 27 kg per square meter (10.5 lb per square foot) with at least one documented weight-related comorbidity to satisfy Aetna’s prior authorization criteria for Wegovy.
Adolescents aged 12 to 17 need a BMI at or above the 95th percentile for their age and sex. BMI documentation must be current, typically within the last 90 days of the PA submission. Aetna requires height and weight recorded in formal medical records, not self-reported measurements from a patient intake form.
Patients with a BMI between 27 and 29 must document at least one qualifying comorbidity. Hypertension, type 2 diabetes, dyslipidemia, sleep apnea, and cardiovascular disease all qualify. The healthcare provider lists these diagnoses in the PA form alongside the specific prescribing rationale for Wegovy.
Qualifying Comorbidities for BMI 27+ Coverage:
- Hypertension (high blood pressure)
- Type 2 diabetes or prediabetes
- Dyslipidemia (high cholesterol or high triglycerides)
- Obstructive sleep apnea
- Established cardiovascular disease
- Non-alcoholic fatty liver disease (NAFLD or MASH)
What Documentation Does Aetna Require for PA?
Aetna requires documentation that includes a current BMI measurement, a confirmed qualifying diagnosis, evidence of at least 6 months of prior lifestyle intervention, and a commitment to a reduced-calorie diet and exercise program going forward, all submitted by the prescribing healthcare provider.
The 6-month lifestyle intervention requirement is where many applications fall short. Patients need documented records from a weight management program, a physician’s office, or a registered dietitian. Informal diet efforts without medical documentation do not count. The good news? Providers can pull records from any prior visit where weight management was discussed.
Continuation of therapy requires proof of clinical progress. Aetna looks for at least 5 percent body weight reduction from the start of treatment, or documented adherence alongside continued medical necessity. Providers submit these measurements and notes at each renewal point to maintain uninterrupted coverage.
Prior Authorization Steps for Wegovy:
- Confirm current BMI measurement in medical records within the last 90 days
- Document qualifying diagnosis: obesity, overweight with comorbidity, or cardiovascular disease
- Gather 6-month lifestyle intervention records from a provider, dietitian, or program
- Have the prescribing provider submit the PA request to Aetna with supporting clinical notes
- Track the decision timeline and set a renewal reminder before the initial 7-month approval expires
Does Aetna Cover Wegovy for Heart Disease?
Yes. Aetna covers Wegovy for cardiovascular risk reduction in adults with established cardiovascular disease who are also obese or overweight, under a separate prior authorization pathway that opened following the FDA’s March 2024 expanded indication approval. This pathway operates independently from the standard weight loss coverage rules.
The cardiovascular pathway matters for patients who might not qualify under the standard weight loss BMI pathway alone. A patient with a prior heart attack and a BMI of 27 (10.5 lb per square foot) now has a legitimate covered route through Aetna. And here is the part most people miss: prior authorization is still required under this pathway, and cardiologist involvement is mandatory for PA submission.
Duration of approval under the cardiovascular indication matches the weight loss pathway: 7 months for initial therapy and 12 months for continuation. Both pathways require renewal documentation showing the patient still meets the clinical criteria for ongoing treatment with Wegovy.
What Is the Cardiovascular Coverage Pathway?
The cardiovascular pathway requires documented atherosclerotic cardiovascular disease (ASCVD) defined as prior myocardial infarction, prior stroke, or symptomatic peripheral arterial disease, combined with a BMI of at least 27 kg per square meter (10.5 lb per square foot) confirmed in recent medical records.
Aetna’s clinical policy bulletin for this pathway requires a cardiologist to prescribe or cosign the prescription. The prescription must specify cardiovascular risk reduction as the clinical indication rather than weight loss. Mislabeling the indication is a common reason for denial under this pathway. Providers familiar with Aetna’s clinical policy bulletins avoid this error by reviewing the bulletin before submitting.
The FDA cardiovascular approval was based on the SELECT trial, which showed a 20 percent reduction in major adverse cardiovascular events with semaglutide 2.4 mg versus placebo. Aetna’s coverage policy incorporates this clinical evidence. Coverage details still vary across individual Aetna plan designs, so members must confirm with their specific plan.
Does Aetna Medicare Cover Wegovy?
No. Aetna Medicare Advantage plans generally do not cover Wegovy for weight loss because federal Medicare law classifies weight loss medications as excluded benefits under the original Medicare statute, a restriction in place since Medicare’s founding. That said, exceptions exist when Wegovy is prescribed for a non-weight-loss FDA-approved indication.
Here’s the nuance: Medicare Part D can cover Wegovy when a provider prescribes it specifically for cardiovascular risk reduction in patients with established cardiovascular disease and obesity or overweight. This pathway became available in 2024 following the FDA’s expanded indication. Weight loss as the sole prescribing rationale does not qualify under Medicare rules.
Congress has not passed legislation to broadly expand Medicare coverage for GLP-1 medications for weight loss purposes, despite active proposals as of 2026. Aetna Medicare Advantage members should review their plan’s Summary of Benefits or call member services for the latest formulary information on Wegovy.
When Can Medicare Part D Cover Wegovy?
Medicare Part D covers Wegovy when a provider prescribes it for cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight, following the FDA’s March 2024 expanded approval, but not when weight loss is the standalone prescribing goal.
Medicare Part D formularies vary by carrier and individual plan. An Aetna Medicare Advantage Part D plan may or may not list Wegovy even for the cardiovascular indication. Members must review their plan’s drug list directly or call member services to confirm availability and applicable cost-sharing on their specific plan.
Prior authorization is still required under Medicare Part D for Wegovy, even when prescribed under the cardiovascular indication. The prescribing cardiologist or treating physician must document cardiovascular disease and BMI qualification. Approval periods and renewal timelines mirror those used in commercial Aetna plans.
How Much Does Wegovy Cost With Aetna?
Wegovy’s list price without insurance runs from approximately $1,349 to $1,800 per month, making Aetna coverage a decisive factor in affordability for most patients who need this medication for long-term weight management. With coverage in place, members pay their plan’s copay or coinsurance after meeting the annual deductible. The math changes significantly once coverage applies.
Cost-sharing depends on the formulary tier Wegovy is assigned to. Preferred tier status since July 2025 means lower copays than non-preferred GLP-1 alternatives. Members enrolled in high-deductible health plans pay the full contracted rate until the deductible is satisfied, which can still represent thousands of dollars depending on the plan’s deductible level.
The Wegovy Savings Card from Novo Nordisk reduces out-of-pocket costs to as low as $25 per month for eligible commercially insured patients. This card is not valid for Medicare or Medicaid patients. Members who qualify for both Aetna coverage and the savings card pay the lower of the two amounts at the pharmacy counter.
What Is Wegovy’s Cash Price Without Insurance?
Wegovy’s cash price is approximately $1,349.02 for a one-month supply as of mid-2026, though the exact price varies by dosage strength and pharmacy location across the United States. The 2.4 mg maintenance dose corresponds to that benchmark price point at most major retail pharmacies.
Pharmacy discount programs like GoodRx and SingleCare lower the out-of-pocket price below the list price but rarely reach the levels available through commercial insurance coverage. NovoCare Pharmacy, Novo Nordisk’s direct pharmacy service, offers additional patient assistance programs that require income qualification and enrollment. Ready to speed things up? Get a proven weight loss plan built around the same principles driving Wegovy’s clinical results.
Compounded semaglutide was available as a lower-cost alternative during the FDA shortage period but became less accessible as the shortage resolved. Compounded versions are not FDA-approved products and are not covered by Aetna. Patients should discuss the regulatory status and clinical risks of compounded semaglutide with their healthcare provider before considering this route.
What Happens If Aetna Denies Wegovy?
If Aetna denies Wegovy coverage, members have the right to appeal the decision within the deadline stated in the denial letter, and published data shows that 65 percent or more of well-documented appeals succeed when adequate supporting documentation is submitted. The denial letter is the essential starting point for any appeal.
Common denial reasons include missing BMI documentation, no recorded lifestyle intervention history, a diagnosis outside FDA-approved indications, or prescribing by a provider outside the required specialty for the cardiovascular pathway. The bad news? Most initial denials stem from incomplete paperwork, not from patients being clinically ineligible. Correcting the documentation often reverses the outcome.
Members can file a first-level internal appeal with Aetna. A failed internal appeal opens the door to an external review by an independent organization under federal law. State insurance departments also offer consumer assistance for members who need help navigating the process or understanding their rights.
How Do You Appeal a Wegovy Denial?
An appeal requires a written request submitted to Aetna within the timeframe in the denial letter, supported by medical records, provider notes, and documentation that directly addresses the specific reason stated for the denial. The treating provider is the most important partner in building a successful appeal.
The treating physician should write a letter of medical necessity explaining why Wegovy is clinically appropriate for this specific patient. This letter references FDA-approved indications, clinical guidelines from the American Heart Association and The Obesity Society, and the patient’s specific medical history. Successful appeals cite named clinical evidence rather than general statements about the drug’s effectiveness.
If the internal appeal fails, an independent external review is available under federal law and is binding on Aetna. State insurance regulators can also provide guidance and, in some states, extend appeal deadlines or add additional review layers for patients who need more time to gather supporting documentation.
What Alternatives Exist If Aetna Won’t Cover Wegovy?
When Aetna excludes Wegovy from coverage, patients can check whether other FDA-approved GLP-1 medications on their formulary, such as Zepbound (tirzepatide) or liraglutide (Saxenda), carry different coverage status under the same Aetna plan. Being denied for one GLP-1 does not mean all GLP-1 options are off the table.
The Wegovy Savings Card from Novo Nordisk reduces the cash price to as low as $25 per month for eligible commercially insured patients paying out of pocket. NovoCare Pharmacy and pharmacy discount programs provide additional savings avenues. These programs do not require insurance approval but do not eliminate the high base cost of the medication entirely.
Non-GLP-1 weight loss medications, including Qsymia, Orlistat, and Contrave, may be covered by Aetna plans that exclude GLP-1 drugs. These alternatives have lower price points but also different efficacy and side effect profiles compared to semaglutide. Our nutritionists at Eat Proteins recommend reviewing the full formulary with a healthcare provider to identify the most effective covered option for each individual patient.
Alternatives When Aetna Denies Wegovy:
- Zepbound (tirzepatide): may be covered on the same Aetna plan at a different formulary tier
- Liraglutide (Saxenda): older GLP-1 with a separate formulary status
- Qsymia or Contrave: non-GLP-1 weight loss medications that may be covered
- Wegovy Savings Card: reduces cash price to $25 per month for eligible patients
- NovoCare Pharmacy: direct savings program from Novo Nordisk
- GoodRx or SingleCare: pharmacy discount programs for patients paying out of pocket
Ready for Your Free Wegovy Coverage Guide From Eat Proteins?
You have the facts. Most Aetna commercial plan members now have a path to Wegovy coverage following the July 2025 formulary update. But coverage is not automatic, and prior authorization requirements trip up patients who are otherwise clinically eligible. Don’t let incomplete paperwork stand between a patient and the medication a provider recommends.
The first move is to call Aetna member services, pull up the drug formulary on the Aetna website, and work with a healthcare provider on the specific prior authorization documentation. Members with established heart disease have a separate cardiovascular pathway that bypasses the standard weight loss BMI thresholds entirely.
Our team at Eat Proteins has built a free guide covering GLP-1 medication coverage, protein-focused meal plans, and diet strategies that support weight management alongside these medications. The plan matters as much as the prescription. Get it below and stop guessing at the details.